Sodium reduction trial by urinary Na/K self-monitoring

Sodium reduction trial by urinary Na/K self-monitoring - The Naghama Na/K Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030934

Enrollment

240

Registered

2018-04-01

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Self monitoring of urinary Na/K at home One-month cross-over design Self monitoring of blood pressure, body composition, and step counts at home. Two-month including the Na/K self-monitoring period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants in the Nagahama study

Exclusion criteria

Exclusion criteria: Pregnancy Hemodialysis Pacemaker implantation Insulin therapy Renal functional decline [renal failure, chronic kidney disease, nephrosis syndrome] Albuminuria [>++ by urine test paper, or urinary albumin >100 mg/dl] Hepatic diseases [cirrhosis, hepatic failure] Heart diseases [ischemic diseases, heart failure, bradycardia, arrhythmia] Cancer Chronic inflammatory bowel disease Chronic diarrhea, or history of dehydration Orthostatic dysregulation, or syncope Hypotension [systolic blood pressure <100 mmHg] Low body weigh [body mass index <16.5 kg/m2]

Design outcomes

Primary

Measure	Time frame
Changes in spot-urine Na/K at one and two month after starting the intervention.	—

Secondary

Measure	Time frame
Changes in sodium intake measured using 24-hour urine sample, and blood pressure and body weight measured at home.	—

Countries

Japan

Contacts

Public ContactYasuharu Tabara

Kyoto University Graduate School of Medicine

tabara@genome.med.kyoto-u.ac.jp075-751-4157

Outcome results